# Stage 6 Completion Report — PMDA/IF Product-Level Registration (2026-06-05)

## Scope completed (operator-side)

| Workstream | Status |
|------------|--------|
| Gap 36-key product register | **36/36** rows addressed |
| Gap document register (new) | **210** rows (6 document types × 35 products with primary) |
| Gap batch manifests | `GAP-001` … `GAP-013` (+ `GAP-000_prep`) |
| CHILD→gap reconciliation | **26** keys logged |
| CHILD C-001 IF audit | **8** keys — `interview_form` notes only, no IF URLs |
| Knowledge `*.md` | **unchanged** (13 upload targets) |
| Preview / collision export | **unchanged** |

## Gap primary outcomes

| Category | Count | Notes |
|----------|-------|-------|
| `verified_primary_source` | 35 | Includes web-verified gap-only + CHILD reconciliation |
| `document_absent_domestic_unapproved` | 1 | `nimodipine` — no domestic PMDA product page |

## Representative gap-only products (pmda.go.jp verified 2026-06-05)

| drug_key | product | pmda_product_url |
|----------|---------|------------------|
| edaravone | ラジカット点滴静注バッグ30mg | `.../02/1190401G1026?user=1` |
| ozagrel | カタクロット注射液40mg | `.../02/3999411H3026?user=1` |
| clazosentan | ピヴラッツ点滴静注液150mg | `.../02/2190418A1023?user=1` |
| fasudil | エリル点滴静注液30mg | `.../02/2190414A1033?user=1` |

## Validators (post-Stage 6)

- 14/14 operator validators: **PASS**
- `external_ready_candidates=0`
- `migration_ledger_rows=576` / `reference_file_count=576` (557 prior + 19 Stage 6 artifacts)

## Explicit non-claims

- Not clinical approval, pharmacist sign-off, or facility confirmation
- Not Custom GPT upload safe (`custom_gpt_upload_safe` remains false on CHILD package)
- Not Preview approved; not collision RAG executed
- Interview Form / RMP individual URLs: **mostly `document_unchecked`** (CHILD 127 + gap)

## Residual / next operator work

1. Pharmacist review of representative products vs facility formulary
2. Per-product Interview Form URL verification on pmda.go.jp (CHILD C-002+ batches)
3. Stage 5A: real Preview + RAG 21-question evidence
4. Stage 7: integrated drug-profile physical layer (after review scope defined)

## Key paths

- [pmda_product_source_register_gap_supplement.csv](../../reference_archive/neurosurgery_gap_supplement_package_v3_full_residual_20260603/01_SOURCE_REGISTERS/pmda_product_source_register_gap_supplement.csv)
- [pmda_document_source_register_gap_supplement.csv](../../reference_archive/neurosurgery_gap_supplement_package_v3_full_residual_20260603/01_SOURCE_REGISTERS/pmda_document_source_register_gap_supplement.csv)
- [STAGE6_RECONCILIATION_LOG.md](../../reference_archive/neurosurgery_gap_supplement_package_v3_full_residual_20260603/11_INTEGRATION_GUIDES/STAGE6_RECONCILIATION_LOG.md)
